Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
{{familytree | | | | | | | | | | | | |!| | | | | | | | | }} | {{familytree | | | | | | | | | | | | |!| | | | | | | | | }} | ||
{{familytree | | | | | | | | | | | | C01 | | | | | | |C01=Histopathologic examination}} | {{familytree | | | | | | | | | | | | C01 | | | | | | |C01=Histopathologic examination}} | ||
{{familytree | | | | | |,|-|-|-|-|-|-|+|-|-|-|-|. | {{familytree | | | | | |,|-|-|-|-|-|-|+|-|-|-|-|-|.| | }} | ||
{{familytree | | | | |D01| | | | | D02| | | | D03 | |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}} | {{familytree | | | | |D01| | | | | D02| | | | | D03 | |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}} | ||
{{familytree | | | | | |!| | | | | | |!| | | | |! | {{familytree | | | | | |!| | | | | | |!| | | | | |!| | }} | ||
{{familytree | | | | |E01| | | | | E02 | | | | E03 | | |E01=Additional tests specific to location of metastasis|E02=• Octreoscan<br> • Plasma chromogranin A|E03=Gender specific tests}} | {{familytree | | | | |E01| | | | | E02 | | | | | E03 | | |E01=Additional tests specific to location of metastasis|E02=• Octreoscan<br> • Plasma chromogranin A|E03=Gender specific tests}} | ||
{{familytree | | | | | |!| | | | | | | | | | | |!| | | }} | {{familytree | | | | | |!| | | | | | | | | | | |!| | | }} | ||
{{familytree | |,|-|-|-|+|-|-|-|.| | | | | | |,|-|^|-|.| | }} | {{familytree | |,|-|-|-|+|-|-|-|.| | | | | | |,|-|^|-|.| | }} | ||
{{familytree | F01 || F02 | | F03 | | | | | | | | F04 | | | F05 | | |F01=bone|F02=Ing|F03=Supra|F04=dasd|F05=asd}} | {{familytree | F01 || F02 | | F03 | | | | | | | | F04 | | | F05 | | |F01=bone|F02=Ing|F03=Supra|F04=dasd|F05=asd}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 19:42, 10 October 2018
| Tumor of unknown primary origin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • Full medical history and physical exam • Basic blood and bichemical analysis • CT scan of chest, abdomen, and pelvis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Histopathologic examination | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | Neuroendocrine carcinoma | Adenocarcinoma and poorly differntiated carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional tests specific to location of metastasis | • Octreoscan • Plasma chromogranin A | Gender specific tests | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| bone | Ing | Supra | dasd | asd | |||||||||||||||||||||||||||||||||||||||||||||||||||